Literature DB >> 2198188

Elevated plasma endothelin in patients with diabetes mellitus.

K Takahashi1, M A Ghatei, H C Lam, D J O'Halloran, S R Bloom.   

Abstract

Plasma concentrations of endothelin, a vasoconstrictor peptide released from vascular endothelial cells, have been measured by radioimmunoassay in 100 patients with diabetes mellitus and 19 healthy subjects. The plasma immunoreactive-endothelin concentrations were found to be greatly raised in the patients with diabetes (1,880 +/- 120 fmol/l, mean +/- SEM) compared with the healthy subjects (540 +/- 50 fmol/l, p less than 0.005). The elevation of immunoreactive-endothelin could not be explained by secondary changes in blood pressure or renal disease and did not correlate with the presence of diabetic retinopathy, duration of diabetes mellitus, fasting blood glucose or serum fructosamine. Fast protein liquid chromatographic analysis of the diabetic plasma immunoreactive-endothelin showed three forms, one in a very big molecular weight position, one intermediate and one in the position of endothelin-1 itself. No material appeared in the positions of endothelin-2 and 3. Chromatographic analysis of normal plasma showed only the big molecular weight peak while material in the endothelin-1, 2 or 3 positions was below detection. The elevation of endothelin in diabetic patients may be a marker of, and further exacerbate, their vascular disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198188     DOI: 10.1007/bf00403325

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  17 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  Endothelin binding sites in porcine aortic and rat lung membranes.

Authors:  S M Kanse; M A Ghatei; S R Bloom
Journal:  Eur J Biochem       Date:  1989-06-01

3.  Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide.

Authors:  M Yanagisawa; A Inoue; T Ishikawa; Y Kasuya; S Kimura; S Kumagaye; K Nakajima; T X Watanabe; S Sakakibara; K Goto
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

4.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

5.  The immune response to glucagon in conjugated form.

Authors:  G Senyk; D E Nitecki; L Spitler; J W Goodman
Journal:  Immunochemistry       Date:  1972-02

6.  Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells.

Authors:  I Komuro; H Kurihara; T Sugiyama; M Yoshizumi; F Takaku; Y Yazaki
Journal:  FEBS Lett       Date:  1988-10-10       Impact factor: 4.124

Review 7.  Endothelial cell function in diabetic microangiopathy.

Authors:  M Porta; M La Selva; P Molinatti; G M Molinatti
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

8.  Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin.

Authors:  Y Itoh; M Yanagisawa; S Ohkubo; C Kimura; T Kosaka; A Inoue; N Ishida; Y Mitsui; H Onda; M Fujino
Journal:  FEBS Lett       Date:  1988-04-25       Impact factor: 4.124

9.  Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells.

Authors:  Y Hirata; H Yoshimi; S Takata; T X Watanabe; S Kumagai; K Nakajima; S Sakakibara
Journal:  Biochem Biophys Res Commun       Date:  1988-08-15       Impact factor: 3.575

10.  The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics.

Authors:  R J Jarrett; P McCartney; H Keen
Journal:  Diabetologia       Date:  1982-02       Impact factor: 10.122

View more
  86 in total

1.  Plasma endothelin-1 levels in Behçet's disease.

Authors:  T Uslu; C Erem; M Tosun; O Deger
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

2.  Impaired cutaneous reactive hyperaemia during hypoglycaemia in young insulin-dependent diabetic patients and healthy controls.

Authors:  J Aman; C Berne; U Ewald; T Tuvemo
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

Review 3.  Endothelial regulation of vascular tone.

Authors:  P Vallance
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

Review 4.  Endothelial dysfunction in diabetes: multiple targets for treatment.

Authors:  Hong Ding; Chris R Triggle
Journal:  Pflugers Arch       Date:  2010-03-18       Impact factor: 3.657

5.  Endothelin-1 response to glucose and insulin among African Americans.

Authors:  Stephanie DeLoach; Yonghong Huan; Constantine Daskalakis; Bonita Falkner
Journal:  J Am Soc Hypertens       Date:  2010-08-21

6.  Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes.

Authors:  Weiguo Li; Aisha I Kelly-Cobbs; Erin M Mezzetti; Susan C Fagan; Adviye Ergul
Journal:  Can J Physiol Pharmacol       Date:  2010-08       Impact factor: 2.273

7.  Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.

Authors:  Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-28       Impact factor: 3.619

Review 8.  Vascular reactivity in diabetes mellitus.

Authors:  Ajay Chaudhuri
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

9.  Plasma endothelin-1 concentrations in patients with retinal vein occlusions.

Authors:  A Iannaccone; C Letizia; S Pazzaglia; E M Vingolo; G Clemente; M R Pannarale
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

10.  Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.

Authors:  Mohammed Abdelsaid; Handong Ma; Maha Coucha; Adviye Ergul
Journal:  Life Sci       Date:  2014-01-13       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.